City of Hope Comprehensive Cancer Center
Beckman Research Institute
Duarte, CA
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
Not currently accepting
CAMMA-1
Phase 1B Clinical Trial Studying the Safety, Activity, and Effectiveness of Cevostamab in Treating People with Relapsed or Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- FCRH5
- Phase 1
Accepting patients
CA088-1005
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Learn more- CAR T Cell
- CELMoD
- GPRC5D
- Phase 1
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
BMS-986453
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Learn more- CAR T Cell
- BCMA
- GPRC5D
- Phase 1
Accepting patients
Mezigdomide Post Abecma Treatment
A Phase 1 Study of Mezigdomide (CC-92480) and Dexamethasone Post Idecabtagene Vicleucel in Relapsed Multiple Myeloma
Learn more- CELMoD
- Maintenance
- Phase 1
Accepting patients
CREST Study
Cardiovascular Reserve Evaluation in Survivors of Transplantation (CREST)
Learn moreAccepting patients
GOCART
Geriatric (G) Assessment Guided Optimization (O) to Accelerate Functional Recovery After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Patients 60 Years and Older With B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma (GOCART)
Learn more- Randomization
- Phase 2
Accepting patients
AZD0305
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
Learn more- PARP Inhibitor
- Phase 1/2
Accepting patients
CAMPERR
cfDNA Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse
Learn more- Observational Trial
Accepting patients
JNJ-79635322
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
Learn more- BCMA
- GPRC5D
- Tri-specific Antibody
- Phase 1
Accepting patients
aMMbition
A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
Learn more- Bispecific Antibody
- CAR T Cell
- BCMA
- GPRC5D
- Randomization
- Phase 2